Clinical trial
Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia
NCT00208143 · Creighton University, Other · Completed
Key facts
| NCT number | NCT00208143 |
|---|---|
| Title | Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia |
| Official title | Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone |
| Lead sponsor | Creighton University, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder, Substance Abuse, Substance Dependence |
| Intervention type | Drug |
| Interventions | Quetiapine, Risperidone |
| Enrollment | 20 |
| Start date | Nov 1, 2003 |
| Completion | Dec 1, 2005 |
| First posted | Sep 21, 2005 |
| Last update posted | Dec 13, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: